SEC Fines Biopharma Co. Execs Over Hidden FDA Findings
By Sydney Price · January 16, 2026, 8:40 PM EST
Former executives of Spero Therapeutics will pay over $187,000 to settle the U.S. Securities and Exchange Commission's claims they downplayed the likelihood that the U.S. Food and Drug Administration would reject...
To view the full article, register now.